Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1895344 Plus Topoisomerase-1 Inhibitors in Advanced Solid Tumors
NCT04514497Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elimusertib in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), pancreatic adenocarcinoma (PDAC) and 1 more (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 21 days and Occurrence of Grade 4 Hematologic Adverse Events. Started Oct 2021; status: active, not recruiting.
02
Drugs
elimusertib
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)pancreatic adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT04514497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514497.